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Antituberculosis drug-related liver injury (ATLI) is the most prevalent hepatotoxicity in
many countries. Whether monitoring liver tests is beneficial to prevent this potentially
grave adverse drug reaction (ADR) is open to debate. The Taiwan Drug Relief Foundation
(TDRF) was established by the Taiwan Food and Drug Administration to collect severe cases
of ADR and carry out drug injury relief tasks. Our intention was to explore the role of
monitoring liver tests in the susceptibility and severity of ATLI from the database of this
foundation. All cases of suspected ATLI collected by the TDRF from 1999 to 2012 were
reviewed. The basic demographic data, clinical course, and laboratory data of these pa-
tients were analyzed. A total of 57 cases with severe ATLI were verified and enrolled into
this study. There was a high mortality (71.9%) in this cohort. Twenty-four cases (42.1%)
were chronic viral hepatitis B carriers, who had higher baseline serum aminotransferase
level than noncarriers. The patients without monitoring liver tests had higher peak serum
alanine aminotransferase, bilirubin levels, and mortality (adjusted odds ratio, 8.87; 95%
confidence interval ¼ 1.32e59.41; p ¼ 0.024) than those with monitoring liver tests. In
conclusion, patients with severe ATLI whose records were collected by the TDRF have a
high mortality. Patients without follow-up monitoring liver tests had more severe liver
injuries and higher mortality than those with monitoring live tests. To alleviate this
potentially grave ADR, checking of liver biochemical tests prior to antituberculosis treat-
ment and periodic monitoring of these tests thereafter are highly suggested.
Copyright ª 2013, Food and Drug Administration, Taiwan. Published by Elsevier Taiwan
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Drug-induced liver injury (DILI) is the major cause of acute
liver injury in the United States and in many other countries
[1,2]. It is also the most common single reason for with-
drawing an approved drug in the United States. Many strate-
gies and endeavors have been launched to prevent this
inevitable adverse drug reaction (ADR) preclinically and
postmarkedly [1]. However, progress in this field seems slow.
More efforts should be exerted to mitigate this potentially
grave ADR.
Tuberculosis (TB) has recently resurged as a hazardous
threat to worldwide public health, which is caused by the
growing prevalence of drug-resistant mycobacterium TB
strains and the increasing number of acquired immunodefi-
ciency syndrome (AIDS) patients [3]. Regimens containing
isoniazid, rifampicin, and pyrazinamide are traditionally used
as the first line of therapy for TB. However, hepatotoxicity
frequently develops in patients receiving these drugs [4e10].
Antituberculosis drug-related liver injury (ATLI) is the most
prevalent DILI in Taiwan and many other countries [4e7].
Chronic hepatitis B infection, which was reported to be a risk
factor of ATLI, is also endemic in Taiwan. To prevent this DILI,
regular monitoring liver tests was suggested by the Center for
Disease Control (CDC), Taiwan, for all TB patients [8]. How-
ever, this is only recommended to special high-risk groups,
such as patients with chronic viral infection, AIDS, and
chronic ethanol consumption, as well as pregnant women in
the United States [9]. Whether regularmonitoring liver tests is
beneficial to prevent ATLI is open to debate.
The Taiwan Drug Relief Foundation (TDRF) has been
established by the Taiwan Food and Drug Administration,
Department of Health, Taiwan, as a nonprofit organization
designated to carry out drug injury relief tasks since 1999 [11].
The premises on which this organization is based are mani-
fold. The core activities of the foundation include issuance of
relief payments to the approved claimants, analysis of the
causal relationship between injuries and suspected drugs, and
research or survey for medication safety-related issues. There
have been more than 1,000 applicants for compensation to
date. Overall, the top drugs for relief payout in DILI were anti-
TB agents [12].
To our knowledge, no study has been conducted to check
on the value of monitoring liver tests in identifying grave DILI
induced by anti-TB drugs. In addition, most of the previous
studies concerning the risk factors of ATLI are retrospective
case-control studies or prospective cohort study based on one
or a few hospitals or regions [4e10]. The degree of liver injury
in these studies ranged from mild to severe. Most of the pa-
tients with mild to moderate ATLI may have an “adaptation”
to anti-TB agents, whichmanifests with normalization of liver
tests even with continuation of anti-TB treatment [10]. In
contrast, the severe form of ATLI may have ominous out-
comes despite discontinuing all drugs for TB [4e10]. There-
fore, focusing on the severe form of ATLI is a cost benefit in
clinical practice and pharmacovigilance. Based on the appli-
cants’ database of TDRF, we tried to explore the role of
monitoring liver tests in the susceptibility and severity of
ATLI.2. Methods
Those who experienced serious ADR resulting in hospitaliza-
tion, disability, or death can apply to the TDRF for economic
relief. The medical records of all applicants to the TDRF were
first scrutinized by two experts, and then reviewed by the
board committee sponsored by the Department of Health of
Taiwan. All applications with suspected ATLI from 1999 to
May 2012 were enrolled into this study.
The inclusion criteria of ATLIwere: (1) an increase in serum
alanine aminotransferase (ALT) level greater than twice the
upper limit of normal value (ULN) during treatment, according
to the criteria established by the International Consensus
Meeting [13]; (2) a Roussel Uclaf Causality Assessment Method
score greater than 5 (when classified as “probable” or “highly
probable” drug-induced hepatitis), as derived from the Inter-
national Consensus Meeting [14].
Patients who had any of the following conditions were
excluded from the study: (1) positive serum IgM antibody to
hepatitis A virus when ALT or aspartate aminotransferase
elevated; (2) other hepatic or systemic diseases thatmay cause
liver dysfunction, such as alcoholic hepatitis, autoimmune
hepatitis, primary biliary cirrhosis, Wilson’s disease, hemo-
chromatosis, stones or tumors of liver and biliary tract, shock,
hypoxia, heart failure, and respiratory failure; (3) elevation of
serum ALT level less than two times the ULN during anti-TB
treatment; (4) insufficient data for assessment.
For evaluating the influence of viral hepatitis infection
status to ATLI, hepatitis B and C carriers were enrolled into the
analysis. However, the included patients must meet the
aforementioned inclusion and exclusion criteria. The defini-
tion of hepatitis B and C carriers was positive serum hepatitis
B surface antigen or antihepatitis C antibody for more than 6
months.
The latency of a liver injury was regarded as time of drug
administration to first abnormal liver tests. To explore the role
of monitoring liver tests, patients were divided into two
groups. The first group was the monitoring group, which
included the patients who had liver biochemical tests at least
two times in the first 2 months of anti-TB treatment, or had
liver tests at least twice in the 1st month of treatment, if the
ATLI occurred in the 1st month. The second group is the non-
monitoring group, which included those without liver
biochemical tests after the anti-TB treatment until the occur-
rence of overt hepatitis. Those patients who had undergone
only one-time liver tests after the anti-TB treatment were
enrolled into the nonmonitoring group, because one-time liver
tests were deemed not sufficient enough, and checking of liver
tests in the 2nd, 4th, and 8th weeks after treatment was rec-
ommended by the TB guidelines of the Taiwan CDC [8].
This study was approved by the Institutional Review Board
of Taipei Veterans General Hospital, and is in accordance with
the Helsinki Declaration of 1975.
The ManneWhitney U test and Fisher’s exact test were
used to compare the variables between groups as appropriate.
The multivariate logistic regression test was applied to eval-
uate the risk factor of mortality (SPSS 19.0 for Windows; SPSS
Inc., Chicago, IL, USA). A two-tailed p value below 0.05 was
considered statistically significant.
Table 1 e Clinical characteristics of patients with severe ATLI.
Patient no. Age/sex ATT
combination
Latency of
LFI (wk)
Virus
inf./type
Serum
examination
LFT before
treatment
LFT after
treatment
Jaundice
1a 71/M R/I/P/E 2 ND ND ND >5 times þ
2a 54/F R/I/P/E 3.8 þ/B ND ND >5 times þ
3a 60/M R/I/P 1.4 þ/B HBsAg(þ) Normal >5 times þ
4a 59/F R/I/P/E 14.3 þ/B HBsAg(þ) Normal >5 times þ
5a 55/M R/I/P/E 6 ND ND Normal >5 times þ
6 68/F R/I/P/E 8 þ/C HBsAg()
HCV Ab(þ)
Normal >5 times þ
7a 41/M R/I/P/E 12 þ/B HBsAg(þ) ND >5 times þ
8a,b 62/M R/I/P/E 20 þ/B HBsAg(þ) ND >5 times þ
9 25/F R/I/P/E 6  HBsAg()
Anti-HCV()
Normal >5 times þ
10a 44/M R/I/P/E 3  HBsAg()
HCV Ab()
Normal >5 times þ
11a 57/M R/I/P/E 5  HBsAg()
Anti-HCV()
Normal >5 times þ
12a 51/F R/I/P/E 22  HBsAg()
Anti-HCV()
Normal >5 times þ
13 56/M R/I/P/E 6  HBsAg()
Anti-HCV()
Normal >5 times þ
14a 21/M R/I/P/E 5  HBsAg()
Anti-HCV()
Normal >5 times þ
15 69/F R/I/P/E 16  Anti-HBs Ab(þ)
Anti-HBc Ab(þ)
Normal >5 times þ
16a 82/M R/I/P/E 3  HBsAg()
Anti-HCV()
Normal >2 times and
<3 times
þ
17a,b 71/M R/I/P/E 8 þ/B HBeAg()
Anti-HBe(þ)
Normal >5 times þ
18a 63/F R/I/P/E 6.4  HBsAg()
HBeAg()
Anti-HCV()
Normal >5 times þ
19a 76/M R/I/P/E 6.1  HBsAg()
Anti-HCV()
Normal >5 times þ
20a 75/M R/I/P/E 3  HBsAg()
Anti-HCV()
Normal >5 times þ
21b 55/M R/I/P/E 13 þ/B HBsAg(þ)
Anti-HCV()
Normal >5 times þ
22a,b 57/M R/I/P/E 21.3 þ/B HBsAg(þ)
Anti-HBs()
Anti-HBC IgM()
<2 times
normal
>5 times þ
23a,b 48/M R/I/P/E 2 þ/B HBsAg(þ)
Anti-HCV()
Normal >5 times þ
24a 76/M R/I/P/E 2 þ/C Anti-HCV(þ) >2 times and
<3 times
>3 times and
<5 times
þ
25a 54/M R/I/P/E 5  HBsAg()
HCV Ab()
Normal >5 times þ
26a 65/M R/I/P/E 2  HBsAg()
HCV Ab()
Normal >5 times þ
27a,b 52/M R/I/P/E 8 þ/B HBsAg(þ)
Anti-HCV()
Normal >5 times þ
28 34/M R/I/P/E 10  HBsAg() <2 times
normal
>5 times þ
29a,b 51/M R/I/P/E 10 þ/B HBsAg(þ)
Anti-HBc(þ)
Normal >5 times þ
30a 80/M R/I/P/E 7  HBsAg()
Anti-HCV()
Normal >5 times þ
31a 46/M R/I/E 4 þ/B HBsAg(þ) Normal >2 times and
<3 times
þ
32 72/M R/I/E 1.2 ND ND Normal >5 times þ
33a 68/M R/I/E 20 þ/B HBsAg(þ)
HBeAg()
Anti-HCV()
Normal >5 times þ
34a,b 62/M R/I/P/E 16 þ/B HBsAg(þ)
HCV-Ab()
Normal >5 times þ
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Table 1 e (continued )
Patient no. Age/sex ATT
combination
Latency of
LFI (wk)
Virus
inf./type
Serum
examination
LFT before
treatment
LFT after
treatment
Jaundice
35a 67/M R/I/P/E 6  HBsAg()
Anti-HCV()
<2 times
normal
>5 times þ
36a,b 79/M R/I/P/E 4 þ/B HBsAg(þ)
HBeAg()
HCV Ab()
<2 times
normal
>3 times and
<5 times
þ
37a 53/M R/I/P/E 0.86  HBsAg()
Anti-HCV()
Normal >5 times þ
38 61/M R/I/P/E 1.4  HBsAg()
HCV Ab()
Normal >2 times and
<3 times

39a,b 48/M R/I/P/E 13 þ/B HBsAg(þ)
Anti-HCV()
Normal >5 times þ
40 49/M R/I/P/E 25 þ/B HBsAg(þ)
Anti-HCV()
HBeAg()
Normal >3 times and
<5 times
þ
41a 59/F R/I/P/E 15 þ/B HBsAg(þ)
HBeAg()
HBeAb()
Normal >5 times þ
42a,b 83/M R/I/P/E 10 þ/B HBsAg(þ)
HCV-Ab()
Normal >5 times þ
43a,b 79/M R/I/E 5 þ/B HBsAg(þ)
HCV-Ab()
Normal >5 times þ
44a 79/M R/I/P/E 6  HBsAg()
Anti-HCV()
Normal >5 times þ
45 85/M R/I/P/E 4  HBsAg()
Anti-HCV()
Normal >3 times and
<5 times

46a 81/M R/I/E 4 þ/B HBsAg(þ)
HCV-Ab()
<2 times
normal
<2 times
normal
þ
47 4/F I 12  HBsAg()
HCV Ab()
ND >5 times þ
48 74/M R/I/P/E 5  HBsAg()
Anti-HCV()
<2 times
normal
>5 times þ
49a 67/M R/I/P/E 12.4 þ/B HBsAg(þ)
HBeAg()
<2 times
normal
>5 times þ
50 79/F R/I/P 18.4 þ/B, C HBsAg(þ)
Anti-HCV(þ)
ND >2 times and
<3 times
þ
51a 83/M R/I/P/E 7.3  HBsAg()
Anti-HCV()
Normal >5 times þ
52a 50/M R/I/P/E 5  HBsAg() Normal >5 times þ
53 42/F R/I/P/E 5.1  HBsAg()
Anti-HCV()
Normal >5 times þ
54a 71/M R/I/P/E 4  HBsAg()
Anti-HCV()
Normal >5 times þ
55 52/F R/I/P/E 6.6  HBsAg()
Anti-HCV()
Normal >5 times þ
56a 83/M R/I/P/E 1  HBsAg()
Anti-HCV()
Normal >5 times þ
57 61/M R/I/P/E 17.6 þ/B HBsAg(þ)
HBeAg()
Normal >5 times þ
ATLI ¼ antituberculosis drug-related liver injury; ATT ¼ antituberculosis treatment; E ¼ ethambutol; I ¼ isoniazid; LFI ¼ liver function
impairment; LFT ¼ liver function test; ND ¼ no available data; P ¼ pyrazinamide; R ¼ rifampicin.
a These patients died.
b HBV-DBA viral load: 100,000 copies/mL.
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From 1999 to May 2012, there have been 1596 applicants for
drug relief in Taiwan. The most frequent ADR was skin dis-
orders, followed by immune system disorders and DILI.
Among the 125 cases diagnosed as DILI, the leading culpritdrugs were anti-TB agents (57 cases, or 45.6% of all DILI). The
clinical characteristics of these 57 patients are shown in
Table 1. The male/female ratio of these patients was 3.75
(78.9% vs. 21.1%, Table 2). The patients were relatively old
(60.816.6 years). Forty-three (75.4%) patients had normal
liver biochemical tests prior to the anti-TB treatment. Fifty-
two cases (91.2%) had peak serum ALT greater than 5 ULN,
Table 2 e Characteristics of chronic hepatitis B carriers and noncarriers with severe ATLI.
All patients (n ¼ 57) Hepatitis B carriers (n ¼ 24) Noncarriers (n ¼ 33)
Male/Female 45/12 20/4 25/8
Age (y)a 60.8  16.6 62.1  12.1 59.1  20.5
Baseline ALT (U/L)a 29.4  22.5 35.8  18.0 24.8  24.6y
After treatment
Latency (wk)a 8.2  6.2 11.4  6.8 5.8  4.4y
Peak serum ALT (U/L)a 1304.5  968.3 1458.8  1188.1 1192.3  771.6
Peak serum bilirubin (mg/dL)a 22.8  12.4 23.8  11.2 22.0  13.4
Mortality 41 (71.9%) 20 (83.3%) 21 (63.6%)
yp < 0.01 as compared with hepatitis B carriers.
ALT ¼ alanine aminotransferase; ATLI ¼ antituberculosis drug-related liver injury.
a Mean  standard deviation.
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(42.1%) cases had chronic viral hepatitis B infection and three
with chronic hepatitis C infection. In hepatitis B virus (HBV)
carriers, 12 patients were positive for HBV DNA when ATLI
was diagnosed.
HBV carriers had significantly higher baseline ALT levels
and longer latency than the noncarriers (p < 0.01, Table 2).
However, there was no significant difference in terms of age,
sex, peak serum ALT, and bilirubin levels between these two
groups. Although HBV carriers had a trend of higher mortality
than noncarriers (83.3% vs. 63.6%), the rate did not reach
statistical significance.
The comparison between monitoring liver tests group and
nonmonitoring group is shown in Table 3. There was no sta-
tistical discrepancy in terms of sex, hepatitis virus B infection
status, baseline ALT levels, and latency between the two
groups. Of note, the nonmonitoring group had higher serum
peak ALT and bilirubin levels, and younger age, compared
with those in the monitoring group. After adjusting for
possible risk factors, nonmonitoring liver test was the only
risk factor of mortality in patients with severe ATLI (odds
ratio, 8.87; 95% confidence interval, 1.32e59.41; p ¼ 0.024;
Table 4).Table 3 e Comparison between monitoring group and
nonmonitoring group in patients with severe ATLI.
Monitoring
(n ¼ 10)
Nonmonitoring
(n ¼ 47)
p
Male/female 7/3 38/9 0.445
Age (y)a 71.4  11.1 58.6  16.8 0.020
Hepatitis B carrier 6 (60.0%) 18 (38.3%) 0.441
Baseline serum
ALT(U/L)a
34.3  22.1 28.3  22.8 0.230
After treatment
Latency (wk)a 9.6  7.4 7.9  5.9 0.705
Peak serum ALT (U/L)a 702.4  614.9 1432.6  985.8 0.012
Peak serum
bilirubin (mg/dL)a
15.1  9.4 24.5  12.4 0.019
Mortality 5 (50%) 36 (76.6%) 0.124
ALT ¼ alanine aminotransferase; ATLI ¼ antituberculosis drug-
related liver injury.
a Mean  standard deviation.4. Discussion
ATLI is the most prevalent DILI in many countries [4e10]. It
may be serious and may have a fatal outcome. The present
national 12 years’ cases analysis in Taiwan revealed that se-
vere ATLI had a very high mortality, and patients without
monitoring liver tests had more severe liver injuries and
poorer outcomes than those with monitoring liver tests.
Prediction or early detection of the high risk patients with
ATLI is always a challenging issue to clinicians, pharmacists,
and all healthcare providers. One of the approaches used is
the application of pharmacogenetics or pharmacogenomics to
correlate the genetic polymorphisms of drug-metabolizing
enzymes and ATLI [1,7]. Our previous studies have shown
that genetic polymorphisms of N-acetyltransferase 2, cyto-
chrome P450 2E1, glutathione S-transferase M1, and manga-
nese superoxide dismutase (MnSOD, SOD2)may be associated
with higher risks of ATLI [15e17]. However, these types of
genetic biomarkers warrant further large-scale international
studies to validate their real role in the early identification of
high-risk groups. Furthermore, these pharmacogenetic assays
are still costly and inconvenient for clinical application. We
therefore considered that monitoring liver tests may be a
simple approach for the early detection and prevention of
ATLI.
Regular monitoring liver tests was highly suggested by the
Taiwan CDC for all TB patients, which included assaying liver
biochemical tests prior to anti-TB treatment and at the 2nd,
4th, and 8th weeks after treatment [8]. Thereafter, the ne-
cessity and frequency of monitoring will depend on the status
of chronic viral hepatitis infection and clinical condition of theTable 4 e Multivariate analysis of risk factors for
mortality in severe ATLI.
Risk factors Odds ratio 95% CI p
Nonmonitoring 8.87 1.32e59.41 0.024
Hepatitis B carrier 4.13 0.89e19.10 0.070
Sex 3.71 0.77e17.84 0.102
Age 1.04 0.99e1.09 0.117
ATLI ¼ antituberculosis drug-related liver injury; CI ¼ confidence
interval.
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recommended for high-risk groups only, such as patients with
chronic viral hepatitis infection, AIDS, and chronic ethanol
consumption, and pregnant women [9]. This is attributed to
the relatively low incidence of ATLI in the United States,
compared with that Taiwan and many other countries. Hep-
atitis B infection, which is a risk factor for the susceptibility
and severity of ATLI in previous reports, is prevalent in
Taiwan [4e6]. In the present study, nearly half of the patients
wereHBV carriers. Thus, the consensuswas that patientswith
chronic viral hepatitis should be followed up with liver tests
regularly. However, more than half of our patients were not
HBV carriers. Moreover, around 15% patients without hepati-
tis B or C infection had ATLI in our previous studies [15,16].
Therefore, whether or not the patient is a hepatitis B carrier,
the incidence of ATLI is relatively high in Taiwan and many
other countries. Because it is difficult to predict whomay have
grave ATLI, we suggested regular monitoring of liver tests for
all patients receiving anti-TB treatment. The present study
provides supporting evidence to this recommendation. How-
ever, the cost benefit of this approach and the frequency of
monitoring liver tests are still debatable. Although further
large-scale case-control prospective studies are warranted to
elucidate the real role of monitoring, regular assessment of
liver tests remains a simple way to ensure the early detection
of severe ATLI.
In this study, hepatitis B carriers had higher baseline ALT
than noncarriers (35.8  18.0 U/L vs. 24.8  24.6 U/L, p ¼ 0.001),
which concurs with our expectation. Although hepatitis B
carriers had higher mortality (83.3% vs. 63.6%), higher mean
peak serum ALT (1,458 U/L vs. 1,192 U/L), and peak serum
bilirubin (23.8 mg/dL vs. 22.0 mg/dL) than noncarriers, the
rates did not reach statistical significance. The first explana-
tion is that all the patients enrolled in this study had severe
DILI, and it may be difficult to further detect the subtle dif-
ferences of severity between hepatitis B carriers and non-
carriers. The second possibility is the limited number of cases
included in this study. However, it is not easy and rather time-
consuming to collect the verified nationwide severe cases
with ATLI in 12 years.
Aged patients have been reported to be more vulnerable to
anti-TB drugs [5,8e10,15,16]. The patients in our study were
relatively old (60.8  16.6 years), which is consistent with
previous reports [5,15,16]. It is noticeable that the patients
with monitoring were older than those without monitoring in
this study (71.4 vs. 58.6 years, p ¼ 0.02). It is probable that
healthcare providers may pay more attention to the elderly
and evaluating their liver tests more frequently.
Only the severe cases were allowed to apply for drug relief
compensation, which explains why this study cohort had a
highmortality. The incidence of severe liver injury induced by
anti-TB drugs is about 1% in the general population, most of
whommay have jaundice [10]. Based on the estimation of Hy’s
law [18], at least 10% of the severe cases have a dismal
outcome or mortality, which is lower than the 72% mortality
noted in this study. We believed that many of the severe cases
with DILI were not reported to our foundation, and only those
involved in very severe or mortality cases may have been
motivated to apply for drug relief. Thus, it should be noted
that the enrolled patients in this study only represent themost severe of cases, which comprise our target group as part
of our efforts to mitigate mortality.
Furthermore, because of the spontaneous nature of these
reports, the data from the TDRF in this study cannot be used
as an incidence study. Extrapolating the results in this study
to the general population is limited and warrants further
justification.
In conclusion, patients with severe ATLI by TDRF have a
high mortality rate. Patients without monitoring liver tests
have more severe liver injuries and higher mortality than
those with monitoring liver tests. To mitigate this ominous
ADR, checking of liver tests prior to anti-TB treatment, and
regular monitoring of liver function thereafter are highly
recommended.Conflicts of interest
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